Essential Hypertension, Type 2 Diabetes Mellitus
Conditions
Brief summary
The objective of this clinical study is to evaluate the pharmacokinetics and the safety after administration of BR1019 and co-administration of BR1019-1 and BR1019-2 in healthy volunteers
Interventions
Sponsors
Boryung Pharmaceutical Co., Ltd
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
19 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
* Those who have body mass index (BMI) within the range of 18.0 to 30.0kg/m² at screening visit * In case of a male subject, Those who weigh 50 kg or more * In case of a female subject, Those who weigh 45 kg or more * Those who decide to voluntarily participate after listening to and understanding the detailed explanation of this clinical trial and who sign a written consent to comply with the subject's precautions during this clinical trial.
Exclusion criteria
* Those who have taken drugs that induce and inhibit metabolizing enzymes such as barbiturate within 30 days prior to the first day of administration or have taken ETC, OTC, Oriental medicine, Health functional food concerned about affecting this clinical trial within 10 days prior to the first day of administration. (however, participation is possible considering pharmacokinetics and pharmacodynamics such as Interaction of investigational products, half-life of concomitant drugs, etc.) * Those who have participated in bioequivalence tests or other clinical trials administered their investigational products within 6 months prior to the first administration date. (However, the termination for participation in other clinical trials are based on the last administration date of their investigational products) * Those who have a medical history of gastrectomy(Except for simple appendectomy, hernia surgery) or gastrointestinal diseases that may affect the absorption of drugs. * Those who can't discontinue a diet (ex. raw grapefruit, grapefruit juice or its products, etc.) that may affect the absorption, distribution, metabolism, and excretion of the drug within 48 hours prior to the first day of administration. * In the case of a female subject, those suspected pregnancy, pregnant woman, lactating woman.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| AUCτ | 0-48 hours after administration | Area under the concentration-time curve from time zero to time τ |
| Cmax | 0-48 hours after administration | Maximum concentration of drug in plasma |
Countries
South Korea
Outcome results
None listed